Comparative Analysis of Cost-Effectiveness of DMARD–NSAID–Corticosteroid and DMARD–NSAID Combination Therapy in Rheumatoid Arthritis Patients at Ciremai Hospital
Jurnal Ilmu Kesehatan (JIKSAN) · 2026
DOI: 10.65099/p0as9x37 ↗Kurz gefasst
Fachartikel in der Zeitschrift Jurnal Ilmu Kesehatan (JIKSAN), 2026. Verfasst von Rosdaniati und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Rheumatoid Arthritis (RA) is a persistent autoimmune disorder that leads to chronic joint inflammation and markedly diminishes patients’ quality of life. Standard RA management typically involves combination pharmacotherapy, including Disease-Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), and corticosteroids.
Purpose
This study was designed to analyze the cost-effectiveness of triple-drug therapy (DMARD–NSAID–corticosteroid) in comparison with double-drug therapy (DMARD–NSAID), and to explore determinants influencing RA treatment in the outpatient setting of Ciremai Hospital.
Method
The research applied a retrospective observational method with a cross-sectional approach, utilizing patient medical records from 2020 to 2025. Therapeutic effectiveness was evaluated by identifying the proportion of patients who exhibited decreased erythrocyte sedimentation rate (ESR) values. Economic assessment was conducted through the calculation of the Average Cost-Effectiveness Ratio (ACER) and the Incremental Cost-Effectiveness Ratio (ICER).
Result
The analysis showed that the majority of patients were within the 40–60-year age range (60%) and were predominantly women (83.3%). The mean direct medical cost per patient receiving triple therapy (IDR 3,049,466) exceeded that of patients receiving double therapy (IDR 2,116,391). From a clinical perspective, triple therapy demonstrated superior effectiveness (88.2%) relative to double therapy (69.2%). The ACER for triple therapy amounted to IDR 3,466,439 per effectiveness unit, whereas double therapy yielded an ACER of IDR 3,066,517 per effectiveness unit, indicating greater cost-efficiency for double therapy. The ICER was determined to be IDR 4,911,974.
Zitieren
APA
Rosdaniati, Hidayat, M., & Jagaddhita, A. (2026). Comparative Analysis of Cost-Effectiveness of DMARD–NSAID–Corticosteroid and DMARD–NSAID Combination Therapy in Rheumatoid Arthritis Patients at Ciremai Hospital. Jurnal Ilmu Kesehatan (JIKSAN). https://doi.org/10.65099/p0as9x37
Vancouver
Rosdaniati, Hidayat M, Jagaddhita A. Comparative Analysis of Cost-Effectiveness of DMARD–NSAID–Corticosteroid and DMARD–NSAID Combination Therapy in Rheumatoid Arthritis Patients at Ciremai Hospital. Jurnal Ilmu Kesehatan (JIKSAN). 2026. doi:10.65099/p0as9x37
BibTeX
@article{Rosdaniati2026,
author = {Rosdaniati and Hidayat, M.Taufik and Jagaddhita, Amelia},
title = {Comparative Analysis of Cost-Effectiveness of DMARD–NSAID–Corticosteroid and DMARD–NSAID Combination Therapy in Rheumatoid Arthritis Patients at Ciremai Hospital},
journal = {Jurnal Ilmu Kesehatan (JIKSAN)},
year = {2026},
doi = {10.65099/p0as9x37}
}
EUVIMED